IBio SG&A Expenses 2010-2024 | IBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

IBio sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

IBio sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$159.1B
Vertex Pharmaceuticals (VRTX)	$124.6B
Bristol Myers Squibb (BMY)	$118.6B
Gilead Sciences (GILD)	$114.8B
CSL (CSLLY)	$88.8B
Regeneron Pharmaceuticals (REGN)	$86B
GSK (GSK)	$71.3B
Argenex SE (ARGX)	$35.6B
Alnylam Pharmaceuticals (ALNY)	$33.3B
BioNTech SE (BNTX)	$24.8B
Biogen (BIIB)	$24B
Illumina (ILMN)	$22.6B
BeiGene (BGNE)	$18.8B
Moderna (MRNA)	$15.3B
Incyte (INCY)	$15B
Genmab (GMAB)	$14B
Insmed (INSM)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.5B
Vaxcyte (PCVX)	$11.6B
Bio-Techne Corp (TECH)	$11.5B
Sarepta Therapeutics (SRPT)	$10.4B
Exelixis (EXEL)	$10B
Revolution Medicines (RVMD)	$9.7B
QIAGEN (QGEN)	$9.6B
Exact Sciences (EXAS)	$9.4B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$9.3B
Roivant Sciences (ROIV)	$8.6B
Repligen (RGEN)	$8B
Ascendis Pharma (ASND)	$7.5B